spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Acetyl esterase for the characterisation of glycosylation in EPO

Ludger Ltd

Acetyl esterase (sialate-O-acetylesterase) is a useful tool to remove 9-, 8- and 7-O-acetyl groups from EPO biopharmaceutical glycans

Acetyl esterase (sialate-O-acetylesterase) is a useful tool to remove 9-, 8- and 7-O-acetyl groups from EPO biopharmaceutical glycans because these sugars and their acetylation are believed to be essential factors for the function, efficacy and half-life of the drug in patients. This enzyme can also be used for the characterisation of other highly sialylated biotherapeutics such as FSH and blood clotting factors. Reference: Biochem J. 2015 Dec 1;472(2):157-67. doi: 10.1042/BJ20150388. Epub 2015 Sep 16.

A paper entitled "Analysis of three epoetin alpha products by LC and LC-MS indicates differences in glycosylation critical quality attributes, including sialic acid content" has been accepted for publication by Analytical Chemistry. This work was the result of a collaboration between the University of Reading, University of Sheffield and Ludger and acetyl esterase was used for this study. Reference: Anal Chem. 2017 Jun 9. doi: 10.1021/acs.analchem.7b00353. [Epub ahead of print] PMID: 28509534

Acetyl esterase (sialate-O-acetylesterase) is available to order from Ludger: Kit containing enzyme and buffer sufficient for 50 samples: Cat No LZ-ACASE-KIT
phone +44 (0) 1865 408 554
email info@ludger.com
web www.ludger.com
email Ludger Ltd, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Denny Bros Group continues its support of Packaging Innovations

A world leading print company is preparing to showcase its renowned labelling and printing solutions at next month’s prestigious Packaging Innovations show.
More info >>


White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement